GH Research Stock (NASDAQ:GHRS)
Previous Close
$7.30
52W Range
$5.12 - $14.99
50D Avg
$8.39
200D Avg
$10.17
Market Cap
$370.44M
Avg Vol (3M)
$64.48K
Beta
0.74
Div Yield
-
GHRS Company Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RCUS | Arcus Biosciences, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ANNX | Annexon, Inc. |
| CSBR | Champions Oncology, Inc. |
| GPCR | Structure Therapeutics Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| PHVS | Pharvaris N.V. |
| RZLT | Rezolute, Inc. |
| MOLN | Molecular Partners AG |
| PMVP | PMV Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| IKNA | Ikena Oncology, Inc. |
| JANX | Janux Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| PEPG | PepGen Inc. |